Correction: JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants

Abstract

JC polyomavirus (JCV) carriers with a compromised immune system, such as in HIV, or subjects on immune-modulating therapies, such as anti VLA-4 therapy may develop progressive multifocal leukoencephalopathy (PML) which is a lytic infection of oligodendrocytes in the brain. Serum antibodies to JCV mark infection occur only in 50-60% of infected individuals… (More)
DOI: 10.1371/journal.ppat.1004084

7 Figures and Tables

Topics

  • Presentations referencing similar topics